Chemistry:TM-38837

Short description: Chemical compound

TM-38837

Clinical data
ATC code	none
Identifiers
IUPAC name 1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
CAS Number	1253641-65-4
PubChem CID	49779607
ChemSpider	29361353
Chemical and physical data
Formula	C30H25Cl2F3N4OS
Molar mass	617.51 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(C1=NN(C2=CC=C(Cl)C=C2Cl)C(C3=CC=C(C#CC4=CC=C(C(F)(F)F)C=C4)S3)=C1CC)NN5CCCCC5
InChI InChI=1S/C30H25Cl2F3N4OS/c1-2-23-27(29(40)37-38-16-4-3-5-17-38)36-39(25-14-11-21(31)18-24(25)32)28(23)26-15-13-22(41-26)12-8-19-6-9-20(10-7-19)30(33,34)35/h6-7,9-11,13-15,18H,2-5,16-17H2,1H3,(H,37,40) Key:VQOCBFYUDSBDCZ-UHFFFAOYSA-N

TM-38837 is a small molecule inverse agonist/antagonist of the CB₁ cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials.

TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB₁ receptor antagonists such as rimonabant.

See also

• AM-6545

External links

• Experimental obesity drug avoids brain effects that troubled predecessors, press release